Richard Alby, Hsu Joey, Baum Patricia, Alterman Ron, Simon David K
Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Division of Neurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Case Rep Neurol. 2019 Jun 26;11(2):199-204. doi: 10.1159/000500951. eCollection 2019 May-Aug.
Chorea-acanthocytosis (ChAc) is a rare autosomal recessive neurodegenerative disease due to mutation of the VPS13A gene encoding the protein chorein. ChAc is a slowly progressive disorder that typically presents in early adulthood, and whose clinical features include chorea and dystonia with involuntary lip, cheek, and tongue biting. Some patients also have seizures. Treatment for ChAc is symptomatic. A small number of ChAc patients have been treated with bilateral deep brain stimulation (DBS) of the globus pallidus interna (GPi), and we now present an additional case. Patient chart, functional measures, and laboratory findings were reviewed from the time of ChAc diagnosis until 6 months after DBS surgery. Here, we present a case of ChAc in a 31-year-old male positive for VPS13A gene mutations who presented with chorea, tongue biting, dysarthria, weight loss, and mild cognitive dysfunction. DBS using monopolar stimulation with placement slightly lateral to the GPi was associated with significant improvement in chorea and dysarthria. This case adds to the current state of knowledge regarding the efficacy and safety of bilateral GPi-DBS for symptomatic control of drug-resistant hyperkinetic movements seen in ChAc. Controlled trials are needed to better assess the impact and ideal target of DBS in ChAc.
舞蹈病-棘红细胞增多症(ChAc)是一种罕见的常染色体隐性神经退行性疾病,由编码舞蹈病蛋白的VPS13A基因突变引起。ChAc是一种缓慢进展性疾病,通常在成年早期发病,其临床特征包括舞蹈症和肌张力障碍,伴有不自主的唇部、颊部和舌部咬伤。一些患者还会出现癫痫发作。ChAc的治疗是对症治疗。少数ChAc患者接受了双侧苍白球内侧部(GPi)深部脑刺激(DBS)治疗,我们现在报告另外一例。回顾了从ChAc诊断到DBS手术后6个月的患者病历、功能指标和实验室检查结果。在此,我们报告一例31岁男性ChAc患者,其VPS13A基因突变阳性,表现为舞蹈症、咬舌、构音障碍、体重减轻和轻度认知功能障碍。采用单极刺激且电极放置在GPi稍外侧的DBS治疗使舞蹈症和构音障碍得到显著改善。该病例补充了目前关于双侧GPi-DBS对ChAc中耐药性运动过多症状控制的疗效和安全性的认识。需要进行对照试验以更好地评估DBS在ChAc中的影响和理想靶点。